Weight-loss clinic marketing compliance 2026 — GLP-1 legality, compounded semaglutide state-by-state, Meta and TikTok policy and the off-label promotion boundary
A working field guide for medical weight-loss clinic owners, hormone and metabolic health practice CFOs, and growth heads running GLP-1 advertising programs in the United States. Written against the FDA compounding framework at 21 USC 353a and 353b, the Federal Food, Drug, and Cosmetic Act off-label promotion rules, Meta's Personal Attributes and health-and-wellness policies, TikTok's Community Guidelines and health-content restrictions, and the state medical and pharmacy board layers that govern the specific words a clinic may use in patient-facing communication.
- The GLP-1 receptor agonist category includes Wegovy (semaglutide 2.4 mg, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly) — both FDA-approved specifically for chronic weight management — and Ozempic and Mounjaro, which are FDA-approved for type 2 diabetes but not for weight loss. Prescribing the diabetes brands for weight loss is off-label; advertising them for weight loss shares the off-label promotion exposure of any other off-label copy.
- Compounded semaglutide is federally permissible only under specific 503A and 503B compounding conditions. The FDA has, at various points, restricted compounding when brand drugs come off the drug-shortage list. State pharmacy law varies. Florida, Arizona and Texas have historically been permissive; California and New York apply narrower state rules; every jurisdiction requires current confirmation with counsel because the regulatory posture shifts quarterly.
- Meta's Personal Attributes policy prohibits ad copy that asserts or implies the viewer's weight or body concern. In the US, weight-loss ads are not banned outright as in some other jurisdictions, but they must be calibrated to wellness and aspiration framing rather than personal-attribute-addressed copy.
- TikTok's health policy restricts ads for prescription medications and restricts organic promotion of unapproved uses. Physician-verified educational content on mechanism, patient selection and clinical experience is broadly permitted; ads and creator content that promote specific compounded products draw enforcement.
- Google Ads permits licensed medical weight-loss services under the Healthcare and Medicines policy. Naming specific prescription products triggers restricted-medicines review. Ads for compounded versions of FDA-approved brand-name drugs are generally not permitted in the ordinary retail channel.
- Dallas, Texas LLC
- US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“When I first approached Ichelon Consulting, my YouTube channel was stuck and despite my own efforts, it was not growing. They created a specific strategy which was based on SEO, and completely evaluating the channel, which worked great and has propelled our YouTube channel to new heights. Because of the channel growth, we have seen new patient consultations coming on a regular basis.”
The GLP-1 product landscape and why it matters for marketing compliance
GLP-1 receptor agonists are the fastest-growing category in weight-management pharmacotherapy. Understanding what is FDA-approved for what indication is the foundation of every compliance decision in the vertical.
- Wegovy (semaglutide 2.4 mg, Novo Nordisk). FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for adolescents 12 years and older with obesity. Cardiovascular outcomes indication also approved.
- Zepbound (tirzepatide, Eli Lilly). FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Obstructive sleep apnea indication added subsequently.
- Ozempic (semaglutide, Novo Nordisk). FDA-approved for type 2 diabetes and separately for cardiovascular risk reduction in certain populations. Not FDA-approved for weight loss.
- Mounjaro (tirzepatide, Eli Lilly). FDA-approved for type 2 diabetes. Not FDA-approved for weight loss.
- Saxenda (liraglutide 3 mg, Novo Nordisk). FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for adolescents 12 to 17 years with obesity.
Advertising a diabetes brand for weight loss is off-label promotion. Advertising Wegovy or Zepbound for weight loss is on-label. This distinction structures every downstream compliance decision — copy that names a diabetes brand alongside weight-loss claims, or copy that presents diabetes brands interchangeably with weight-loss brands, sits in off-label promotion territory and must be treated as such.
Compounded semaglutide — the 503A and 503B framework, and where state law diverges
Compounding is the preparation of a drug for an individual patient by combining, mixing or altering ingredients. Federal law recognizes two compounding pathways.
503A traditional compounding
Section 503A of the FD&C Act permits state-licensed pharmacies and physicians to compound drugs for individually identified patients pursuant to a valid prescription. The compounder must operate in compliance with state pharmacy law, use bulk substances that appear on FDA's list of substances that may be used, and meet specific labeling and record-keeping requirements. A 503A compounder is not registered with the FDA.
503B outsourcing facilities
Section 503B, added by the Drug Quality and Security Act of 2013, permits outsourcing facilities to compound drugs in bulk without patient-specific prescriptions. 503B facilities register with the FDA, must comply with current good manufacturing practice (cGMP), and are inspected by the FDA on a schedule. 503B facilities can supply compounded medications to clinics on a wholesale basis.
The drug shortage carve-out
Both 503A and 503B permit the compounding of drugs that are on FDA's official drug-shortage list, subject to certain conditions. Semaglutide and tirzepatide have appeared on and been removed from the shortage list at various points during the GLP-1 supply cycle. When a drug comes off the shortage list, the federal justification for compounding narrows and enforcement risk increases correspondingly.
State pharmacy law variation — permissive versus restrictive states
State pharmacy law adds a second layer on top of federal 503A and 503B. Some states are broadly permissive of physician-prescribed compounded medications delivered through licensed compounding pharmacies; others are narrower. The picture is regularly changing and any practice advertising compounded GLP-1s in multiple states needs current state-by-state confirmation before publishing marketing that presumes availability.
Historically permissive
- Florida. State pharmacy law permits 503A compounding with physician prescription for individual patients, and 503B outsourcing facilities operate widely. Florida Board of Pharmacy applies its ordinary regulatory oversight.
- Arizona. Compounding permitted under state pharmacy law with physician prescription; Arizona State Board of Pharmacy enforcement focused on labeling and record-keeping.
- Texas. Compounding permitted under state pharmacy law with physician prescription; Texas State Board of Pharmacy actively regulates both 503A and 503B activity.
Historically more restrictive
- California. California Board of Pharmacy applies narrower rules on office-use compounding and physician dispensing. Practices must confirm the pathway for each compounded formulation.
- New York. New York State Board of Pharmacy applies specific rules on out-of-state compounding pharmacies dispensing into New York. Advertising that presumes availability in NY without confirmation is exposed.
- New Jersey, Illinois, Massachusetts. Each applies its own pharmacy board rules on compounding pathways and on the interaction between compounding pharmacies and non-pharmacy clinics.
These lists reflect general regulatory posture and are not a substitute for current legal advice. Regulatory bulletins, state pharmacy board notices and federal shortage-list changes can move a state from one column to another within weeks. The operational rule is that no compounded-GLP-1 campaign should be scaled to multiple states without a written, current legal check on each target state.
Off-label promotion — Ozempic, Mounjaro and the diabetes-brand advertising boundary
Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Prescribing them for weight loss is off-label. Physicians may lawfully do so in the practice of medicine. What is restricted is promotion of the diabetes brand for the off-label weight-loss use, as covered in detail in our companion off-label injectable FDA guide.
The practical rule for weight-loss clinic marketing is:
- Do not name Ozempic or Mounjaro as a weight-loss product in advertising copy.
- Where the clinic prescribes them for weight loss in individual patients, discuss them on the clinic website as options that a licensed physician may prescribe off-label, with clear disclosure of off-label status.
- Use Wegovy, Zepbound and Saxenda as the products to name in weight-loss campaigns, since they are approved for weight loss and the advertising is on-label.
- Where the clinic offers a compounded product, the compounded-versus-branded distinction must be clearly disclosed. Do not present a compounded product as equivalent to Wegovy or Zepbound without qualification.
Meta’s health-and-weight-loss ad policy in the US
Meta's advertising standards treat weight-loss and body-image content as a sensitive category. The two provisions that most affect US weight-loss clinic marketing are:
- Personal Attributes. Ads must not assert or imply personal attributes about the viewer — including body weight, body shape, or medical condition. "Are you struggling with obesity?" fails on the personal-attribute assertion.
- Restrictions on weight-loss product ads. Certain jurisdictions apply an outright ban; in the US, weight-loss ads are heavily restricted but not banned. Ads that promote medical weight-loss services delivered by a licensed physician can pass review when framed as service description rather than personal-condition addressing.
Additional Meta restrictions relevant to weight-loss clinics include the prohibition on targeting minors, on before-and-after imagery in the ad creative (though on the practice's own website, subject to appropriate consent and disclaimers), and on ads that make specific unqualified outcome claims.
Copy patterns that pass Meta review
- "Explore our physician-led medical weight-management program in Dallas."
- "Meet Dr Reddy, our board-certified medical director — read her clinical approach to metabolic health."
- "Learn how our clinical team evaluates GLP-1 candidacy — an educational overview from our practice."
- "Comprehensive care from consultation through follow-up, at our physician-led clinic."
Copy patterns that fail
- "Struggling with weight loss? We can help."
- "Lose 15% of your body weight in 6 months."
- "Are you overweight? Book your consultation now."
- "Wegovy for as little as $299 a month — no questions asked."
TikTok policy — organic educational content, ad restrictions and creator agreements
TikTok's Community Guidelines and separate Advertising Policies restrict content that promotes or provides instructions on obtaining prescription drugs outside a physician-directed context. Prescription medication ads are broadly restricted; healthcare service ads are permitted with additional review.
The nuance for weight-loss clinics is that verified physician creators have significant latitude for educational content — explaining GLP-1 mechanism, discussing patient selection criteria, sharing clinical decision-making in a professional voice, engaging with viewer questions. That content is not treated as an advertisement.
The line is crossed when:
- The creator promotes a specific compounded product with a direct call to action to purchase or book.
- The content pairs a specific product name with an unqualified outcome claim.
- The creator offers a promo code that pays commission on GLP-1 purchases without appropriate disclosure and without physician-review context.
- The content targets minors, either in framing or in known viewer demographics.
Physician creators partnering with a weight-loss clinic should sign an agreement that mirrors the FTC 16 CFR 255 material-connection disclosure standard and adds TikTok-specific commitments — no direct product promotion, no unqualified outcome claims, education-first framing, clinical-context disclosure on any patient-specific content.
Five decisions every US weight-loss clinic must make
1. Product-mention taxonomy
Wegovy, Zepbound, Saxenda for on-label weight-loss copy. Ozempic and Mounjaro referenced only in physician-first-person off-label context on the clinic's own site. Compounded options disclosed with state permissibility and compounded-versus-branded distinction.
2. State-by-state compounding audit
Current written confirmation from counsel for every target state before scaling advertising that presumes availability of a compounded option. Refresh quarterly at minimum.
3. Meta Personal Attributes calibration
Copy calibrated to service description, not personal-condition addressing. Category-level and aspirational, never "are you overweight." Landing pages consistent with the ad.
4. TikTok creator agreements
Written agreement with every physician or influencer creator: material-connection disclosure standard, education-first framing, no unqualified outcome claims, no direct product promotion, clinical-context disclosure on patient-specific content.
5. Google Ads restricted-medicines path
Ad copy that names Wegovy, Zepbound, Saxenda calibrated for restricted-medicines review. Compounded-product ads acknowledged as heavily restricted; alternative campaign structures for compounded offerings.
State medical board rules on weight-loss clinic advertising
Every state medical board has advertising rules that reach weight-loss clinics. The elements that concentrate risk are:
- Unsupported outcome claims. "Guaranteed weight loss," "lose 20 pounds in a month," "results in weeks not months" — all vulnerable to state medical board discipline for unsupported claims.
- Testimonial and before-and-after imagery. Subject to the state's testimonial rules and FTC 16 CFR 255.2 representative-results standard. Every asset accompanied by generally-expected-results disclosure.
- Physician identification. Multiple states require the physician of record to be identified in advertising for medical services.
- Corporate practice of medicine. Where the weight-loss clinic is corporate-owned rather than physician-owned, the CPOM analysis for the state applies.
- Fee-splitting. Where the clinic's payment structure to the physician is percentage-based rather than fair-market-value fee-for-service, state fee-splitting rules apply.
The compounded-medications overlay adds state pharmacy board involvement. Compounded-medication advertising that overstates equivalence to branded products, misrepresents the compounding pathway, or omits the state permissibility caveat is exposed to state pharmacy board enforcement in addition to medical board enforcement.
Where weight-loss compliance sits in the stack
Backed by Ichelon Consulting US leadership
Every GLP-1 marketing engagement is reviewed by a senior member of the Leadership Team with visibility into FDA compounding enforcement patterns, Meta and TikTok health-policy escalations, and the state medical and pharmacy board layers.
Our own tools run inside every engagement
Ichelon Consulting US uses software built by our own product team. Practices can also use most tools on their own, billed in USD.
Weight-loss clinic marketing compliance — common questions
Is compounded semaglutide legal in every US state?
Federal law permits 503A/503B compounding under specific conditions. State pharmacy law varies. Florida, Arizona and Texas have historically been permissive; California and New York apply narrower rules. Confirm with counsel before advertising.
What are FDA 503A and 503B?
503A permits traditional patient-specific compounding by state-licensed pharmacies. 503B permits outsourcing facilities to compound in bulk under FDA registration and cGMP. Both are the vehicles for compounded GLP-1s.
Are Wegovy and Ozempic FDA-approved for weight loss?
Wegovy is approved for chronic weight management. Ozempic is approved for type 2 diabetes, not weight loss — prescribing it for weight loss is off-label.
Are Zepbound and Mounjaro FDA-approved for weight loss?
Zepbound is approved for chronic weight management. Mounjaro is approved for type 2 diabetes, not weight loss — prescribing it for weight loss is off-label.
What does Meta permit for weight-loss ads?
US weight-loss ads are heavily restricted but not banned. Aspiration and service-description framing pass; personal-attribute-addressed copy fails. No targeting of minors. Landing pages consistent with the ad.
What does TikTok permit for GLP-1 content?
Verified physician creators can produce educational content on mechanism, patient selection and clinical experience. Ads and creator content promoting specific compounded products face heavy restriction.
Can weight-loss clinics use Google Ads for GLP-1 services?
Yes for licensed medical weight-loss services under the Healthcare and Medicines policy. Naming specific prescription products triggers restricted-medicines review; compounded-brand ads are generally not permitted in ordinary channels.
What state medical board rules apply?
Every state has rules on truthful presentation of results, disclosure of the physician of record and prohibitions on unsupported claims. California, Florida, Texas and New York are among the most active. State pharmacy boards also regulate the compounding side.
What about telemedicine weight-loss models?
Telemedicine adds interstate practice rules and telehealth-specific advertising requirements. Some states have specific telehealth prescribing and dispensing rules; a clinic operating across state lines needs a per-state compliance review before advertising nationally.
Are lifestyle-only weight-loss ads simpler to run?
Yes, when the clinic offers non-pharmacologic programs (nutrition coaching, behavior change, exercise physiology). The advertising remains subject to FTC substantiation, state medical board rules and Meta Personal Attributes, but the GLP-1 and compounding layers do not apply.
Scope your compliant weight-loss clinic marketing program
Book a 30-minute call with a senior member of the Leadership Team, email the US practice lead, or call the Dallas office. Retainers are custom-scoped per engagement · from $499/month, with GLP-1 marketing audits priced on scope.
Continue the compliance stack
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“When I first approached Ichelon Consulting, my YouTube channel was stuck and despite my own efforts, it was not growing. They created a specific strategy which was based on SEO, and completely evaluating the channel, which worked great and has propelled our YouTube channel to new heights. Because of the channel growth, we have seen new patient consultations coming on a regular basis.”
Common questions
What do compliant weight loss ads look like?
Compliant weight loss ads promise a process, not an outcome: medically supervised programs, eligibility screening and realistic language such as 'results vary.' They name prescription drugs only where the platform allows it and the advertiser is LegitScript certified, avoid before-and-after images on Meta, target adults 18 and over, and never imply compounded drugs are FDA-approved or equivalent to brand products.